Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
NCT06843447 · View on ClinicalTrials.gov ↗
Study Summary
Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came back after treatment. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes. Standard treatment (usual treatment) for people with relapsed high-grade serous ovarian cancer may include: * Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing * Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread Raludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Rescue Medication
- BIOLOGICAL Raludotatug Deruxtecan
- BIOLOGICAL Bevacizumab
Study Locations (16)
Other
- Rambam Health Care Campus ( Site 0202) — Haifa
- Shaare Zedek Medical Center ( Site 0201) — Jerusalem
- Sheba Medical Center ( Site 0200) — Ramat Gan
- Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300) — Barcelona
- Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303) — Madrid
- Hospital Universitario 12 de Octubre ( Site 0304) — Madrid
England
- Royal Marsden Hospital ( Site 0402) — Fulham
- The Royal Marsden NHS Foundation Trust. ( Site 0403) — Sutton
Kentucky
- The University of Louisville, James Graham Brown Cancer Center ( Site 0009) — Louisville
New York
- Memorial Sloan Kettering Cancer Center ( Site 0003) — New York
Texas
- Houston Methodist Hospital ( Site 0010) — Houston
Utah
- START Mountain Region ( Site 0008) — West Valley City
Virginia
- University of Virginia Health System ( Site 0011) — Charlottesville
Barcelona
- Institut Català d'Oncologia - L'Hospitalet ( Site 0302) — L'Hospitalet de Llobregat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2025-04-15 |
| Est. Completion | 2029-03-27 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06843447
The ClinicalTrials.gov registry entry for NCT06843447 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 741 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Ovarian Cancer Recurrent appearing as the primary indexed condition, and to 5 interventions — of which Carboplatin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06843447 reports 16 study locations spanning 10 distinct geographic areas — top geographies include Other, England, Kentucky. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06843447 about?
NCT06843447 is a clinical study titled "A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)". Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came back after treatment. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or ...
What is the current status of trial NCT06843447?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 280 participants. The study started on 2025-04-15. Estimated completion is 2029-03-27.
What conditions does trial NCT06843447 study?
This clinical trial studies the following conditions: Ovarian Cancer Recurrent. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06843447?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Rescue Medication (DRUG), Raludotatug Deruxtecan (BIOLOGICAL), Bevacizumab (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06843447?
This trial is sponsored by Merck Sharp & Dohme, which has 741 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06843447 being conducted?
This trial has 16 study locations across Kentucky, New York, Texas, Utah, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.